StockData

Caris Life Sciences vs Castle Biosciences

CAI and CSTL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CAI and CSTL compare

Caris Life Sciences is the larger company, worth 5.6 times as much as Castle Biosciences ($5.6B against $1.0B).

Caris Life Sciences grew revenue faster over the last twelve months (61.5% versus 9.8% for Castle Biosciences).

Caris Life Sciences keeps more of each dollar of sales as profit, with a net margin of 9.2% compared with −6.1% at Castle Biosciences.

Castle Biosciences scores higher on the StockData Score (11 against 7 for Caris Life Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCAICSTL
Size and price
Market cap$5.6B$1.0B
Share price$19.94$32.98
Change, 1 year−16.4%−1.4%
Change, 5 years–−23.5%
Beta (5Y)2.530.68
Employees1,846883
StockData Score
Total score711 (better)
Valuation score02 (better)
Growth score12 (better)
Performance score33
Health score34 (better)
Dividend score00
Valuation
P/S5.4×2.7× (better)
P/B8.8×2.1× (better)
EV/EBITDA36.5×–
P/FCF195× (better)254×
FCF yield0.51% (better)0.39%
Fair value$10.35$34.22
Margin of safety−92.6%3.6% (better)
Growth
Revenue growth (TTM)61.5% (better)9.8%
Revenue growth, 5Y average–40.6%
Profitability
Gross margin–77.1%
Operating margin13.4% (better)−7.4%
Net margin9.2% (better)−6.1%
FCF margin2.8% (better)1.1%
Return on equity17.2% (better)−4.9%
Return on invested capital26.8% (better)−11.1%
Financial health
Debt / equity0.610.02 (better)
Net debt / EBITDA1.79–
Interest coverage3.3× (better)−51.2×
Current ratio6.71 (better)5.28
Altman Z-score4.736.49 (better)
Piotroski F-score6 (better)4
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Buyback yield0.56%–
Shareholder yield0.56% (better)0.00%
Ownership
Held by institutions54.5%89.5%
Held by insiders64.1%1.9%
Insider net buying, 12 months−$27.4M−$18.4M (better)
Superinvestors holding2–
Short interest, % of float11.3%7.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.